Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 13/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.37 |
| ▸ | MELK | Q14680 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | CIT | O14578 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092166 | 0.87 | PRKCI (0.39) | BRAFCYP2D6CYP2C9JAK3KDR | |
| SCHEMBL4088298 | 0.82 | BRAF (0.39) | BRAFCYP2D6CYP2C9JAK3KDR | |
| Trifluoroacetic Acid SCHEMBL4092015 | 0.81 | JAK3 (0.44) | BRAFCYP2D6CYP2C9JAK3AURKA | |
| SCHEMBL29540587 | 0.79 | JAK3 (0.48) | BRAFCYP2D6CYP2C9JAK3MELK | |
| SCHEMBL101336 | 0.79 | JAK3 (0.48) | BRAFCYP2D6CYP2C9JAK3MELK | |
| Trifluoroacetic Acid SCHEMBL4093224 | 0.79 | TEK (0.44) | BRAFMAPK14 | |
| Trifluoroacetic Acid SCHEMBL4082497 | 0.78 | GRM5 (0.48) | MET | |
| SCHEMBL98624 | 0.77 | MAPK14 (0.47) | BRAFMAPK14ROCK2 | |
| SCHEMBL29540753 | 0.77 | MAPK14 (0.47) | BRAFMAPK14ROCK2 | |
| Trifluoroacetic Acid SCHEMBL4097114 | 0.76 | CTSA (0.36) | BRAFCYP2D6CYP2C9KDRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-8415362-B2 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | BRAF 51/4885CYP2D6 1930/4885CYP2C9 2421/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | BRAF 51/4885CYP2D6 1930/4885CYP2C9 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.